| Purity: | 98 |
|---|---|
| Model Number: | C130H220N44O41 |
| Brand Name: | NJ STERIOD |
| Usage: | Animal Pharmaceuticals |
| Grade Standard: | Medicine Grade |
| Type: | Auxiliaries and Other Medicinal Chemicals |
| Place of Origin: | China (Mainland) |
| CAS No.: | 472-61-546 |
| 96829-58-2: | 1USD(changeable) |
Quick Details
Specifications
Healthy Weight Loss Steroid Orlistat Powder CAS 96829-58-2 for Obesity
Quick Details:
Product name: Orlistat
CAS Numbers: 96829-58-2
Appearance: white needle crystal or powder
Quality standard: CP
Packing specification: 1 kg/bag
Melting point: 45°
Purity: 98.0%
Appearance: White or kind of white crystalline powder, soluble in water.
Usage: Used for curing obesity.
Product Description:
Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli by GlaxoSmithKline in the United Kingdom and the United States. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.
Application:
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug over the course of a year. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). These decrease with time, however, and are the most frequently reported adverse effects of the drug. In the United States and the European Union, orlistat is available for sale without a prescription. Over-the-counter approval was controversial in the United States, with consumer advocacy group Public Citizen repeatedly opposing it on safety and efficacy grounds. Generic formulations of orlistat are available in some countries. A prescription is needed for use in Australia.